Limvorapitak Wasithep, Khawcharoenporn Thana
Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathumthani, Thailand E-mail :
Asian Pac J Cancer Prev. 2015;16(14):5945-50. doi: 10.7314/apjcp.2015.16.14.5945.
A 6-year retrospective cohort study was conducted among Thai hematologic malignancy (HM) patients receiving intensive chemotherapy. Of the 145 eligible patients receiving 893 chemotherapy sessions, 46.9% were female, median age was 52 years, and the most common HM diagnosis was diffuse large B-cell lymphoma (46.2%). Febrile neutropenia (FN) occurred in 14.9% of chemotherapy sessions with an incidence of 24.8 per 1,000 chemotherapy cycles per year. Independent factors associated with FN were receiving the first chemotherapy cycle [adjusted hazard ratio (aHR) 4.1], having hemoglobin ≤100 g/L (aHR 3.7) and platelet ≤140,000/μL (aHR 2.7) on chemotherapy day and receiving acute myeloid leukemia regimens (aHR 20.8). Granulocyte colony stimulating factor was significantly associated with reduced rate of FN when given in those receiving CHOP regimen. With the median follow-up time of 16 months, the overall survival time was significantly longer in patients without FN than those with FN (61.7 vs. 20.8 months; p<0.001).
对接受强化化疗的泰国血液系统恶性肿瘤（HM）患者进行了一项为期6年的回顾性队列研究。在145名接受893个化疗疗程的符合条件的患者中，46.9%为女性，中位年龄为52岁，最常见的HM诊断为弥漫性大B细胞淋巴瘤（46.2%）。发热性中性粒细胞减少症（FN）发生在14.9%的化疗疗程中，每年每1000个化疗周期的发生率为24.8。与FN相关的独立因素包括接受第一个化疗周期[调整后风险比（aHR）4.1]、化疗当天血红蛋白≤100 g/L（aHR 3.7）和血小板≤140,000/μL（aHR 2.7）以及接受急性髓细胞白血病治疗方案（aHR 20.8）。在接受CHOP方案的患者中给予粒细胞集落刺激因子与FN发生率降低显著相关。中位随访时间为16个月，无FN患者的总生存时间显著长于有FN患者（61.7对20.8个月；p<0.001）。
